What is Mauna Kea Technologies?
Mauna Kea Technologies is a pioneering medical device company specializing in advanced cellular imaging solutions. Their flagship Cellvizio® platform offers real-time visualization capabilities, significantly enhancing diagnostic accuracy and guiding surgical interventions across critical medical fields such as gastroenterology, oncology, and pulmonology. The company's commitment to innovation in medical imaging technology positions it at the forefront of healthcare advancements, enabling clinicians to make more informed decisions and improve patient outcomes.
How much funding has Mauna Kea Technologies raised?
Mauna Kea Technologies has raised a total of $68.4M across 6 funding rounds:
Series B
$30M
Debt
$7.5M
Unspecified
$8.4M
Share Placement
$14.7M
Debt
$2.1M
Other Financing Round
$5.8M
Series B (2008): $30M with participation from Seventure Partners, Psilos Group, and Creadev
Debt (2017): $7.5M led by IPF Partners
Unspecified (2019): $8.4M supported by JJDC
Share Placement (2021): $14.7M featuring Johnson & Johnson Innovation and Armistice Capital
Debt (2025): $2.1M backed by Vester Finance
Other Financing Round (2025): $5.8M, investors not publicly disclosed
Key Investors in Mauna Kea Technologies
Johnson & Johnson Innovation
Johnson & Johnson Innovation is a pharmaceutical manufacturing company focused on positively impacting human health through innovation, partnering with entrepreneurs and early-stage businesses to develop healthcare solutions globally.
IPF Partners
IPF Partners is a prominent alternative financing provider exclusively focused on the healthcare sector, offering tailored debt and equity financing solutions to commercial stage digital health, biopharma, healthcare services, and medtech companies.
Seventure Partners
Seventure Partners is an active partner of innovative companies in the fields of digital technologies and life sciences, investing in health, nutrition, fintech, and sustainable blue economy initiatives.
What's next for Mauna Kea Technologies?
With the recent infusion of major strategic investment and a substantial overall funding history of $68.4M, Mauna Kea Technologies is poised for accelerated growth and technological development. This capital backing is anticipated to support the expansion of their Cellvizio® platform into new therapeutic areas and geographical markets. Furthermore, the company is likely to invest in research and development to enhance its imaging capabilities and explore novel applications, solidifying its position as an indispensable tool in modern medical diagnostics and surgery. Strategic partnerships and further financing rounds may follow as the company scales its operations and global reach.
See full Mauna Kea Technologies company page
